|
KMID : 1148920080420000039
|
|
Nuclear Medicine and Molecular Imaging
2008 Volume.42 No. 0 p.39 ~ p.45
|
|
|
Clinical Application of 18F-FDG PET in Gastric Cancer
|
|
Yun Mi-jin
Kim Tae-Sung
Hwang Hie-Seong
|
|
|
Abstract
|
|
|
PET or PET/CT detects only less than 50% of early gastric cancer and 62-98% of advanced gastric cancer.
Therefore, mass screening programs are recommended for all adults over the age of 40 for early detection and early treatment of gastric cancer through endoscopy or various radiological tests. The most important step after diagnosis of gastric cancer is accurate staging, which mainly evaluates tumor resectability to avoid unnecessary surgery. Important factors that affect tumor resectability are whether the tumor can be separated from adjacent organs or important blood vessels, the extent of lymph node metastasis, presence of peritoneal metastasis, or distant organ metastasis. To evaluate the extent of local tumor invasion, anatomical imaging that has superior spatial resolution is essential. There are a few studies on prognostic significance of FDG uptake with inconsistent results between them. In spite of lower sensitivity for lymph node staging, the specificity of CT and PET are very high, and the specificity for PET tends to be higher than that for CT. Limited data published so far show that PET seems less useful in the detection of lung and bone metastasis. In the evaluation of pleural or peritoneal metastasis, PET seems very specific but insensitive as well. When FDG uptake of primary tumor is low, distant metastasis also tends to show low FDG uptake reducing its detection on PET. There are only a few data available in the evaluation of recurrence detection and treatment response using FDG PET or PET/CT. (Nucl Med Mol Imaging 2008;42(suppl 1):39-45)
|
|
|
KEYWORD
|
|
|
gastric cancer, F-18 FDG PET, staging, treatment response
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
  
|
|